Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis

Ads

You May Also Like

Foamix Reports Third Quarter 2015 Financial Results and Provides Business Update

REHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix Pharmaceuticals"), ...